No recent announcements
MaxCyte Inc. develops and commercializes cell engineering technologies, primarily through its ExPERT™ platform, which utilizes non-viral electroporation for high-efficiency transfection across various applications. The company provides services and products that support the development of cell-based therapies, including gene editing, vaccine development, and viral vector production. MaxCyte operates globally, partnering with biopharmaceutical companies to facilitate the advancement of therapies from discovery through clinical manufacturing. Its customers include researchers and developers in the life sciences sector.
MaxCyte Inc. develops and commercializes cell engineering technologies, primarily through its ExPERT™ platform, which utilizes non-viral electroporation for high-efficiency transfection across various applications. The company provides services and products that support the development of cell-based therapies, including gene editing, vaccine development, and viral vector production. MaxCyte operates globally, partnering with biopharmaceutical companies to facilitate the advancement of therapies from discovery through clinical manufacturing. Its customers include researchers and developers in the life sciences sector.
